The 50-day moving average for IMNM moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMNM as a result. In 64 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for IMNM turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Indicator entered the oversold zone -- be on the watch for IMNM's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNM advanced for three days, in 236 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IMNM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 164 of 189 cases where IMNM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.047) is normal, around the industry mean (3.596). P/E Ratio (-7.395) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. IMNM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Aroon Indicator for OCS entered a downward trend on November 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 153 similar instances where the Aroon Indicator formed such a pattern. In 104 of the 153 cases the stock moved lower. This puts the odds of a downward move at 68%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OCS as a result. In 42 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 45%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OCS's RSI Indicator exited the oversold zone, 17 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 46 cases where OCS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for OCS just turned positive on October 21, 2026. Looking at past instances where OCS's MACD turned positive, the stock continued to rise in 33 of 48 cases over the following month. The odds of a continued upward trend are 69%.
Following a +13.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where OCS advanced for three days, in 151 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
OCS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.896) is normal, around the industry mean (3.596). P/E Ratio (-5.428) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. OCS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IMNM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 67 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 74 | |
P/E GROWTH RATING 1..100 | 28 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| IMNM | OCS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 71% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 45% |
| MACD ODDS (%) | 1 day ago 87% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 59% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 60% |
| Advances ODDS (%) | 12 days ago 83% | 12 days ago 75% |
| Declines ODDS (%) | 1 day ago 86% | 3 days ago 66% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 68% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMNM’s FA Score shows that 1 FA rating(s) are green while OCS’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMNM’s TA Score shows that 4 TA indicator(s) are bullish while OCS’s TA Score has 6 bullish TA indicator(s).
IMNM (@Biotechnology) experienced а -11.18% price change this week, while OCS (@Biotechnology) price change was -0.80% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.90%. For the same industry, the average monthly price growth was -16.46%, and the average quarterly price growth was -27.70%.
IMNM is expected to report earnings on Mar 25, 2027.
OCS is expected to report earnings on Mar 22, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, IMNM has been loosely correlated with KYTX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNM jumps, then KYTX could also see price increases.
| Ticker / NAME | Correlation To IMNM | 1D Price Change % | ||
|---|---|---|---|---|
| IMNM | 100% | -5.54% | ||
| KYTX - IMNM | 60% Loosely correlated | -2.52% | ||
| SLDB - IMNM | 53% Loosely correlated | -2.95% | ||
| EDIT - IMNM | 53% Loosely correlated | -4.09% | ||
| MGTX - IMNM | 52% Loosely correlated | -1.97% | ||
| FDMT - IMNM | 50% Loosely correlated | -4.57% | ||
More | ||||
A.I.dvisor indicates that over the last year, OCS has been loosely correlated with PRAX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if OCS jumps, then PRAX could also see price increases.
| Ticker / NAME | Correlation To OCS | 1D Price Change % | ||
|---|---|---|---|---|
| OCS | 100% | -5.11% | ||
| PRAX - OCS | 37% Loosely correlated | -3.37% | ||
| JSPR - OCS | 34% Loosely correlated | -19.16% | ||
| JBIO - OCS | 33% Poorly correlated | +1.66% | ||
| IMNM - OCS | 32% Poorly correlated | -5.54% | ||
| FTH - OCS | 32% Poorly correlated | -9.32% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GJT | 23.21 | 0.24 | +1.04% |
| Synthetic Fixed-Income Securities STRATS 2006-3 AllState Corp | |||
| JLQD | 39.10 | N/A | N/A |
| Janus Henderson Corporate Bond ETF (JLQD) | |||
| GSID | 69.18 | -1.98 | -2.78% |
| Marketbeta INTL Equity ETF (GSID) | |||
| FDLS | 37.20 | -1.10 | -2.87% |
| Inspire Fidelis Multi Factor ETF (FDLS) | |||
| THTA | 14.09 | -1.18 | -7.73% |
| SoFi Enhanced Yield ETF (THTA) | |||